OncoMatch/Clinical Trials/NCT06790082
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Is NCT06790082 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies [68Ga]Ga-FAPI-46 PET/CT for pleural mesothelioma.
Treatment: [68Ga]Ga-FAPI-46 PET/CT — Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging. The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT). The diagnostic accuracy will be determined with histopathology as reference standard. For patients undergoing anticancer treatment (chemotherapy, immunotherapy, other treatment), an additional FAPI PET/CT and an additional FDG PET/CT will be conducted after the study subjects have completed 2-3 series of anticancer treatment. The feasabilitiy of FAPI PET/CT in response evaluation will be investigated. All study specific analyzes will be blinded and will not influence the patient management / treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Mesothelioma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06790082 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages